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cGMP analogue 8-Br-cGMP. Inhibition of HO caused marked 
amplification of PP increase in zymosan-treated organs. CO 
prevented this PP increase cGMP independently. Interesting-
ly, KC activation and simultaneous inhibition of HO aug-
mented the production of prostaglandins D 2 and F 2   and of 
thromboxane A 2 . Accordingly, indomethacin blunted the in-
crease of PP in zymosan/ZnPP-treated livers.  Conclusions: 
 NO restricts the initial PP increase after KC activation by GC-
mediated cGMP. CO from heme degradation limits the in-
crease of PP after KC activation eicosanoid dependently, but 
cGMP independently. 
 
Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Liver function is dependent on intrahepatic microcir-
culation. It has been shown that Kupffer cell (KC) activa-
tion affects the microcirculation of the liver  [1–7] . The 
involved mechanisms are an increased production of va-
soconstrictors  [8–12] , enhanced responsiveness to vaso-
constrictors  [13–15] and an altered production of vasodi-
lators  [16–20] . The best known vasoconstrictors are pros-
taglandins (PGs) such as thromboxane (TX) A 2 and 
cysteinyl leukotrienes like leukotriene C 4 and D 4  [6, 9] ; to 
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 Abstract 
 Background: Portal pressure (PP) results from the interplay 
of vasoconstrictors and vasodilators. Recently, we have 
shown that Kupffer cell (KC) activation increases PP.  Aims: 
The role of the vasodilating compounds nitric oxide (NO) and 
carbon monoxide (CO) was studied. The hypothesis of the 
present study was that these vasodilators counteract the PP 
increase following KC activation.  Methods:  Livers of rats 
weighing 180–200 g were isolated and perfused. KCs were 
activated by zymosan A (cell wall particles from yeast; 150 
  g/ml). The effects of NO and guanylate cyclase (GC) were 
evaluated by the NO synthase inhibitor N G -nitro- L -argi-
nine methylester ( L -NAME; 0.3 m M, and the GC inhibitor
4 H -8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-
one (NS-2028, 1.0   M ); the effects of the heme oxygenase 
(HO) derived compound CO were evaluated by direct admin-
istration of CO or inhibition of HO by zinc protoporphyrin IX 
(ZnPP IX, 1.0   M ).  Results: In isolated perfused rat livers, ad-
ministration of  L -NAME or NS-2028 further raised PP increase 
following KC activation. This effect could be reduced by the 
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the relevant vasodilators account nitric oxide (NO) and 
carbon monoxide (CO)  [21–25] .
 KCs produce a significant amount of  vasoconstrictors 
 [11] , which act on the contractile cells in the liver which 
are hepatic stellate cells and myofibroblasts  [13, 26] . Con-
traction mechanisms are under the control of Ca 2+ -de-
pendent and Ca 2+ -independent pathways  [27] .
 The  vasodilator NO is generated by different nitric ox-
ide synthases (NOS). The constitutively expressed iso-
form endothelial NOS (eNOS) seems to be involved in the 
physiological regulation of hepatic perfusion  [28] . For va-
sodilation, NO stimulates the soluble guanylate cyclase 
(GC) to produce cyclic guanosine monophosphate 
(cGMP) in vascular smooth muscle cells  [29] . CO is pro-
duced by the degradation from protoheme IX to biliver-
din. This step is catalyzed by heme oxygenases (HO) 
which are found in the liver in two different isoforms, the 
inducible isoform HO-1 and the constitutive isoform 
HO-2. In normal livers HO-2 influences the hepatic mi-
crocirculation. This has been shown by investigations 
with the HO inhibitor ZnPP IX  [22] .
 KC activation has been found to influence hepatic mi-
crocirculation in normal livers  [5] . To date, the mecha-
nisms which counteract this portal pressure (PP) increase 
are not well defined. Here, we investigated the effects of 
NO and CO following KC activation in normal livers uti-
lizing an in vitro model with the potential to better un-
derstand the clinical situation. The restriction of PP in-
crease following KC activation is of clinical importance 
in healthy livers. These mechanisms and their therapeu-
tic intervention possibilities are responsible to limit the 
deleterious effects of microcirculatory disturbances in 
liver injury, liver failure or following liver transplantation 
 [30–33] .
 Materials and Methods 
 Animal Studies 
 Animals were ethically treated according to the criteria estab-
lished by the National Academy of Sciences and published by the 
National Institutes of Health, in addition to the legal require-
ments of Germany. All animal experiments were approved by the 
local government (Regierung von Oberbayern, Munich, Germa-
ny) and were reported to the responsible authorities.
 In situ Rat Liver Perfusion Study 
 Male Sprague-Dawley rats (180–200 g; Charles River, Sulzfeld, 
Germany) were anesthetized by intraperitoneal injection of so-
dium pentobarbital (50 mg/kg b.w.). After incision of the abdom-
inal wall, the portal vein was cannulated with a 14-gauge Teflon 
intravenous catheter, and the liver was perfused at a constant flow 
rate. The inferior vena cava was cannulated through the right atri-
um and ligated above the right renal vein. For all experiments, the 
livers were perfused with Krebs-Henseleit solution (pH 7.4, 37  °  C) 
in a non-recirculating manner. The perfusion buffer was gassed 
with a mixture of 95% O 2 and 5% CO 2 using an oxygenator  [34] . 
The portal perfusion pressure (PPP) was monitored continuously. 
The bile duct was cannulated with polyethylene tubing (PE10) in 
order to monitor bile flow. The liver was allowed to stabilize for 
25 min prior to the addition of any substances. During this initial 
25-min stabilization period, liver viability was determined using 
two criteria: (1) the maintenance of stable perfusion pressure and 
(2) lactate dehydrogenase efflux rates of  ! 10 mU/min    g of liver. 
Lactate dehydrogenase activity was analyzed as reported else-
where  [5] . If one of the criteria for viability was not satisfied, the 
experiment was discarded.
 KC Activation 
 Control experiments using Krebs-Henseleit buffer were per-
formed over a 100-min time period (n = 6). To activate KCs, zy-
mosan A (cell wall particles from yeast; 150   g/ml, during min 
40–46 after initiating perfusion, n = 11) was infused into the livers 
as described previously  [11] .
 Infusion of NO, GC and cGMP 
 Rat livers were perfused with Krebs-Henseleit buffer alone for 
control experiments (n = 6) and zymosan (min 40–46, 150   g/ml, 
n = 11) was infused for KC activation. To inhibit NOS, N G -nitro-
 L -arginine methylester ( L -NAME; min 30–100, 0.3 m M , n = 5) was 
infused additionally. Alternatively, for inhibition of GC, 4 H -
8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one (NS-
2028; min 30–100, 1.0   M , n = 5) was administered. The cGMP 
analogue 8-Br-cGMP (min 30–100, 50   M ) was infused in com-
bination with  L -NAME (min 30–100, 0.3 m M ) and zymosan A 
(min 40–46, 150   g/ml, n = 5), NS-2028 (min 30–100, 1.0   M ) and 
zymosan A (min 40–46, 150   g/ml, n = 5) or in combination with 
zymosan A (min 40–46, 150   g/ml, n = 5) alone.
 Effects of HO on CO and cGMP 
 To investigate mechanisms following KC activation and inhi-
bition of HO, livers were perfused with zymosan (150   g/ml) 
from 40 to 46 min together with ZnPP IX (min 30–60, 1   M , n = 
5) and in comparison ZnPP IX alone (min 30–60, 1   M , n = 5). 
Additionally, CO (2.5   M , n = 5) was infused from min 30 to 100 
in order to mimic HO-dependent CO formation. CO solutions 
were prepared as described by Wang  [35] : 250 ml NaCl 0.9% was 
gassed for 15 min via frit. Saturated CO solutions were infused by 
microinfusion pumps reaching a final concentration of 2.5   M in 
the effluent perfusate  [21] . The hypothesis whether CO acts via 
cGMP was tested by additional infusion of 8-Br-cGMP instead of 
CO (min 30–100, 50   M , n = 5).
 PG Production and Its Functional Role 
 Production of the PGD 2 , PGF 2   and TXA 2 was quantified by 
their release into perfusate. PGD 2 and TXB 2 , the stable degrada-
tion product of TXA 2 , was measured in duplicate using radioim-
munoassays (Amersham, Freiburg, Germany). PGF 2   was mea-
sured by an enzyme immunoassay (Assay Designs, Inc., Ann Ar-
bor, Mich., USA). To delineate the functional role of PGs, the 
cyclooxygenase (COX)-1/COX-2 inhibitor indomethacin (min 
30–60, 50   M , n = 5) was infused in combination with zymosan 
(min 40–46, 150   g/ml) and ZnPP IX (min 30–60, 1   M ).
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 Drugs and Reagents 
 Zymosan, indomethacin and dimethyl sulfoxide were ob-
tained from Sigma Chemical Co. (St. Louis, Mo., USA). NS-2028, 
8-Br-cGMP and  L -NAME were obtained from Calbiochem (Bad 
Soden, Germany). Zymosan was suspended directly in perfusion 
buffer. All other reagents were prepared as aqueous stock solu-
tions ( L -NAME) or DMSO stock solutions (NS-2028, 8-Br-cGMP, 
indomethacin). Stock solutions were infused into the portal in-
flow of the perfusion system by microinfusion pumps at a rate of 
50   l/min.
 Statistics 
 All data are expressed as mean  8 SD. Statistical analyses of 
data were performed using a Mann-Whitney U test. p  ! 0.05 was 
considered statistically significant.
 Results 
 NO, GC and cGMP Pathway 
 The free radical NO is a well-known vasodilator. In the 
first part of the study the effects of NO on PP following 
KC activation were studied. The   -glycan-rich zymosan 
was infused to activate KCs. The PPP increased about 
400% following zymosan infusion ( fig.  1 a). In control 
perfusion experiments the PPP did not change over 100 
min ( fig. 1 a). Inhibition of the NOS by  L -NAME increased 
the maximal PPP to a higher degree than the KC activa-
tion by zymosan alone ( fig. 1 a). The maximal PPP follow-
ing zymosan and  L -NAME infusion was diminished by 
the cGMP analogue 8-Br-cGMP ( fig. 1 b). The maximal 
PPP was also enhanced by inhibition of the soluble GC by 
NS-2028 ( fig. 1 b). Again, the infusion of 8-Br-cGMP re-
duced the maximal PPP following the combined admin-
istration of zymosan A and NS-2028 ( fig. 1 b). In contrast, 
infusion of 8-Br-cGMP had almost no effect on PPP fol-
lowing KC activation ( fig. 1 b).
 Prolonged Increase of PPP by Inhibition of HO 
 The concomitant inhibition of HO by zinc protopor-
phyrin IX (ZnPP IX) resulted in a massive and pro-
longed increase of PPP compared to the PPP increase 
caused by the infusion of zymosan alone ( fig.  2 a). In 
contrast, the infusion of ZnPP IX alone increased the 
PPP only slightly ( fig. 2 a). The additional administra-
tion of CO following KC activation and inhibition of 
HO lowered the PPP during the time period from 60 to 
100 min of perfusion time ( fig. 2 b). Interestingly, this 
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 Fig. 1. Increase of PPP following KC activation and effects of NOS. 
 a KCs were activated by administration of zymosan (Zy, 150   g/
ml) from min 40 to 46 ( I , n = 11). Compared to control experi-
ments ( d , n = 6) zymosan increased PPP transiently by about by 
400% ( *  p  ! 0.05). The additional inhibition of NOS by  L -NAME 
(0.3 m M , min 30–100) markedly enhanced this increase of PPP 
( O  , n = 5,  #  p  ! 0.05).  b The augmented increase of PPP by  L -
NAME (0.3 m M , min 30–100,  +  p  ! 0.05, n = 5) was reduced by 
infusion of the cGMP analogue 8-Br-cGMP (50   M , min 30–100, 
 ++  p  ! 0.05, n = 5). Inhibition of the GC by NS-2028 (1.0   M , min 
30–100,  §  p  ! 0.05, n = 5) markedly increased the PPP which was 
again reduced by addition of 8-Br-cGMP (50   M , min 30–100,
 §§  p  ! 0.05, n = 5). Infusion of 8-Br-cGMP (50   M , min 30–100,
n = 5) did not lower the increase of PPP following zymosan infu-
sion (150   g/ml, min 40–46, n = 11). 
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effect was not cGMP-dependent, because the infusion of 
8-Br-cGMP instead of CO had almost no effect on the 
PPP ( fig. 2 b).
 Enhanced PG Production by KC Activation and 
Inhibition of HO 
 The activation of KCs by zymosan resulted in a tran-
sient increase of the formation of PGD 2 , PGF 2   and 
TXB 2 , the stable degradation product of TXA 2 ( fig. 3 a–c). 
In parallel to the increase of PPP the formation of the 
PGD 2 , PGF 2   and TXB 2 were enhanced by the inhibition 
of HO up from min 46 until the end of the experiments 
( fig. 3 a–c).
 Functional Role of the Increased PG Production 
 To address the functional role of the increased PG and 
TXB 2 efflux rates following KC activation and HO inhibi-
tion, the COX inhibitor indomethacin was additionally 
infused. Indomethacin, a simultaneous COX-1 and COX-
2 inhibitor, reduced the profound hemodynamic effects 
by HO inhibition and KC activation ( fig. 4 ).
 Discussion 
 This study describes a novel mechanism of PP increase 
in normal livers by inhibition of HO. There were three 
principal findings of our study: (1) the inhibition of the 
NOS increased the PPP cGMP dependently; (2) the inhi-
bition of HO extended the PPP increase from transient to 
long-lasting following KC activation, and (3) the effect of 
HO was cGMP-independent but based on the increased 
production of PGs and TXB 2 .
 NO and GCs 
 In the first part of this study we investigated the GC 
NO pathway and its potential role to counteract the in-
crease of PPP following KC activation in normal livers. 
The inhibition of the intrahepatic NO formation by  L -
NAME as well as the inhibition of the GC by NS-2028 
enhanced the increase of PPP following KC activation. 
These additional PPP increases were abolished by the 
cGMP analogue 8-Br-cGMP in both settings. Cells with 
contractile potential are mainly the hepatic stellate cells 
 Fig. 2. Prolonged increase of PPP following KC activation and in-
hibition of the HO by ZnPP IX.  a Activation of KCs by zymosan 
(Zy) ( I , 150   g/ml, min 40–46) increased the PPP ( *  p  ! 0.05,
n = 11) compared to control experiments ( y , n = 6). Inhibition of 
HO by ZnPP IX (1   M , min 30–60) in addition to KC activation 
( + , zymosan 150   g/ml, min 40–46, n = 5) increased the PPP to 
a higher maximum compared to the infusion of zymosan alone 
( * *  p  ! 0.05). Additionally, the PPP was elevated until end of ex-
periments ( * *  p  ! 0.05). The infusion of ZnPP IX ( d , 1   M , min 
30–60, n = 5) increased the PPP slightly over control values ( y ,
n = 6).  b The infusion of ZnPP IX (1   M , min 30–100) in addition 
to KC activation by zymosan (150   g/ml, min 40–46) ([2], n = 5) 
increased the PPP significantly ( *  p  ! 0.05) compared to the infu-
sion of zymosan ([1], 150   g/ml, min 40–46, n = 11). The infusion 
of CO ([3], 2.5   M , min 30–100, n = 5) together with KC activation 
by zymosan (150   g/ml, min 40–46, n = 5) and HO inhibition by 
ZnPP IX infusion (1   M , min 30–100, n = 5) reduced significant-
ly ( * *  p  ! 0.05) the PPP increase compared to the simultaneous 
infusion of zymosan (150   g/ml, min 40–46) and ZnPP IX (1   M , 
min 30–100) ([2], n = 5). In contrast, the infusion of the cGMP 
analogue 8-Br-CGMP ([4], 50   M , min 30–100, n = 5) did not 
lower the PPP compared to the combination of KC activation (zy-
mosan 150   g/ml, min 40–46) and inhibition of HO (ZnPP IX
1   M , min 30–100) ([2], n = 5). 
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and the myofibroblasts. Both cell types have been de-
scribed previously to mediate contraction of the hepatic 
microvasculature NO dependently  [18, 26, 27] . Further-
more, effects of NO on contractile cells are cGMP-medi-
ated, which could explain the observed cGMP effects in 
the present study  [36] . Additionally, liver sinusoidal endo-
thelial cells have been described to play an important role 
for the NO pathway  [28, 29, 37] ; however, the interaction 
of all non-parenchymal cell types in sinusoidal blood flow 
regulation has not yet been understood in detail. Hypo-
thetically the imbalance of vasoconstrictors and vasodila-
tors in liver injury is not related to one of the cell types but 
to the interplay of all non-parenchymal cell types. It seems 
of major interest for future studies to compare the vaso-
constrictive and vasodilative potential of each cell type.
 HO and CO 
 In the second part of this study we investigated the 
HO-CO pathway. We demonstrated that the inhibition of 
HO in combination with KC activation increased the 
PPP. KCs and HO have been described to play a major role 
in many liver diseases like acute liver failure  [38–40] and 
ischemia-reperfusion injury  [41] . The hemodynamic ef-
fects of HO following KC activation have however not 
been investigated up to now. We have studied the mecha-
nisms increasing PP in normal and fibrotic livers before 
following KC activation  [5] . Interestingly, the transient 
PPP increase following KC activation was prolonged by 
the additional inhibition of HO. Inhibition of HO alone 
increased the PPP only slightly as it has been described in 
a previous study  [21] . The PPP effects observed in the 
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 Fig. 3. Control of PG formation by HO. Increase of the PPP fol-
lowing KC activation (zymosan (Zy) 150   g/ml, min 40–46) was 
paralleled by an augmented PG efflux. This efflux was further 
enhanced by the additional inhibition of the HO by ZnPP IX
(1   M , min 30–100, each n = 5): ( a ) PGD 2 efflux (control [1] vs. 
zymosan 150   g/ml, min 40–46 [2] vs. zymosan 150   g/ml, min 
40–46 and ZnPP IX 1   M , min 30–100 [3],  *  p  ! 0.05,  * *  p  ! 0.05), 
( b ) PGF 2   efflux (control [1] vs. zymosan 150   g/ml, min 40–46 
[2] vs. zymosan 150   g/ml, min 40–46 and ZnPP IX 1   M , min 
30–100 [3],  *  p  ! 0.05,  * *  p  ! 0.05), and ( c ) TXB 2 efflux (control [1] 
vs. zymosan 150   g/ml, min 40–46 m [2] vs. zymosan 150   g/ml, 
min 40–46 and ZnPP IX 1   M , min 30–100 [3],  *  p  ! 0.05,  * *  p  ! 
0.05). 
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present study can therefore not be the result of the simple 
addition of both PPP increases, resulting from zymosan 
infusion alone or ZnPP IX infusion alone.
 In the next step we investigated the involved mecha-
nisms. The vasodilator CO is produced by the degrada-
tion from heme to biliverdin. Indeed, infusion of CO at-
tenuated the PPP increase by about 40%, but this effect 
was not dependent on cGMP. The lack of effect is not due 
to a low concentration, because the same concentration 
of 8-Br-cGMP was already used in the experiments with 
NO described above in the present study. Interestingly, 
the efflux of the PGD 2 and PGF 2   and the TXA 2 were 
enhanced by the inhibition of the HO in combination 
with KC activation. The functional role of the increased 
PG production was investigated by indomethacin, a 
combined COX-1 and COX-2 inhibitor. The additional 
infusion of indomethacin attenuated the PPP increase 
about 60%. Heme is an apoenzyme of COX  [42] . There-
fore, high concentrations of heme imply high activity of 
COX. Inhibition of HO therefore leads to high amounts 
of heme and consecutively high activity of COX. This 
could explain the increase of the PG efflux and the in-
crease of the PPP following KC activation and HO inhi-
bition.
 Another relevant aspect concerning the protective ef-
fects of HO and CO could be the antioxidative property 
of CO  [43] . Reactive oxygen species play an important 
role in ischemia/reperfusion injury  [34] and in acute liver 
injury. This might on the one side activate hepatic stellate 
cells and on the other side impair endothelial dysfunc-
tion. Protective effects of CO in the present study might 
therefore additionally be related to its antioxidative prop-
erty, but this was not investigated more in detail in the 
present study.
 The HO pathway is also known to play an important 
role in fibrogenesis, liver fibrosis and liver cirrhosis. Re-
cently it has been shown in Mdr2 knockout mice that in-
duction of HO-1 was able to revert portal inflammation 
and fibrosis  [44] . Furthermore, earlier studies demon-
strated the role of HO and CO in the regulation of intra-
hepatic resistance in cirrhotic rat livers  [24] . The role of 
KCs was not investigated in this earlier study but it could 
be hypothesized that the counteracting mechanism of 
HO and CO production is also of relevance in cirrhotic 
livers following KC activation.
 Clinical Implications of This Study 
 This study describes novel mechanisms of counterac-
tion of PP increase in normal livers following KC activa-
tion. Situations of KC activation in the clinical context are 
conceivable in each situation of an increased load in the 
portal vein of TLR agonists like bacterial or fungal prod-
ucts. Clinical examples are ischemia-reperfusion with in-
creased amounts of pathogen-associated molecular pat-
terns, biliary obstruction with cholangitis and sepsis. Mi-
crocirculatory disturbances are observed as shown by the 
present study immediately after the exposure to the TLR-
2 and TLR-9 agonist zymosan. Interestingly, mechanisms 
of counteraction started almost simultaneously. To know 
the counteracting mechanisms seems of clinical rele-
vance for potentially new therapeutic strategies. For ex-
ample, induction of HO seems feasible in the near future 
as a therapeutic intervention.
 In conclusion, our results show that in normal livers 
following KC activation there is a role for NO and for HO 
to influence PPP. We found that NO acts via GC and 
cGMP as a vasodilating mechanism following KC activa-
tion. In contrast, CO does not act via cGMP. The inhibi-
tion of the HO led to an increased PG and TX formation 
following KC activation, which led to a prolonged PPP 
increase. In the context of KC activation, HO are impor-
tant regulators of liver hemodynamics. This knowledge 
can be considered for future therapeutical strategies like 
induction of HO.
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 Fig. 4. Functional relevance of the enhanced amount of PGs in the 
effluent perfusate. The COX inhibitor indomethacin ( d , 50   M , 
min 30–60, n = 5) reduced ( #  p  ! 0.05,  * *  p  ! 0.05) the increase of 
PPP following zymosan (Zy) infusion (150    g/ml, min 40–46) 
and additional administration of ZnPP IX ( + , 1   M , min 30–100, 
n = 5). 
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